Manhattan BioSolutions secures non-dilutive angel funding

by Mbio2018|Published May 1, 2018

Manhattan BioSolutions, Inc. Signs Commercial Evaluation License Agreements with the National Institutes of Health (NIH) for Use of Monoclonal Antibodies in Novel Antibody-Drug Conjugate (ADC) Oncology Programs

NEW YORK, NY / ACCESSWIRE / July 20, 2022 / Manhattan BioSolutions, Inc. today announced it has entered into two commercial evaluation license […]

Published November 7, 2023

Manhattan BioSolutions Enters Into Collaboration Agreements with the NIH and Binghamton University to Develop Novel ADC

Collaboration with National Institutes of Health and Binghamton University to Develop Novel Antibody-Drug Conjugates for Pediatric Cancer New York City, New York […]

Published August 23, 2021

EVQLV and Manhattan BioSolutions Announce Grant Award from UB CAT

New York City, New York Jun 29, 2021 (Issuewire.com) – EVQLV, an innovator in developing artificial intelligence to accelerate how biologic therapies reach patients, […]

Published June 1, 2022

Manhattan BioSolutions Enters into a Research Collaboration And License Option Agreement with Binghamton University for the New Linker-Payload Technology

NEW YORK, NY / ACCESSWIRE / June 1, 2022 / Manhattan BioSolutions, Inc., an emerging biotechnology company developing new classes of therapeutic biologics […]

Back to post list
Next post Manhattan BioSolutions has been awarded REACH grant from the New York State Center For Biotechnology at the Stony Brook University